Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relapsed multiple myeloma: lenalidomide + dexamethasone with or without high-dose melphalan and autologous stem cell transplantation
ISRCTN16345835Phase 3Completed
- Sponsor
- Heidelberg University Hospital
- Start
- Sep 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lenalidomide, dexamethasone and melphalan in multiple myeloma (MM) (2 arms), sponsored by Heidelberg University Hospital. Primary endpoint: Progression-free survival. Started Sep 2010; status: completed.
02
Drugs
lenalidomidedexamethasonemelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN16345835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16345835.